Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients

13.06.2022 - FORT LEE, N.J., June 13, 2022 (GLOBE NEWSWIRE) - Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need ... Seite 1

Related Keywords

Germany ,Hamburg ,United Kingdom ,London ,City Of ,Edinburgh ,Louis Chesler ,Ron Bentsur ,Institute Of Genetics Cancer ,Brain Tumour Group ,Institute Of Cancer Research ,Therapeutics Team ,Nuvectis Pharma Inc ,University Of Edinburgh ,Tumour Group ,Pediatric Solid Tumour Biology ,Cancer Research ,Executive Officer ,